Payment overview · 2025
General Payments
$177.95
10 reported records · 7 companies
Healthcare provider profile · identity verified
John M Jenkins, MD
Allopathic & Osteopathic Physicians|Family Medicine · COLUMBUS, GA · NPI 1700896503
Verified facts
What the public records show
CMS Open Payments records show John M Jenkins, MD received $177.95 in general payments during 2025 across 10 reported records.
Novartis Pharmaceuticals Corporation accounted for 33.0% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 12 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Entresto, Ozempic, Rybelsus.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 18 claims for Linzess by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 106 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 28 claims for Trulicity by this doctor in 2024.
Novartis Pharmaceuticals Corporation reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ENTRESTO as an associated drug or biological on 9346 records involving 6254 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Entresto by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 233 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 19 claims for Rybelsus by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 65 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $58.66 | 33.0% | 3 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $38.07 | 21.4% | 2 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $17.50 | 9.8% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $16.11 | 9.1% | 1 | 2025 |
| Ardelyx, Inc. | Unresolved — no canonical attribution shown | $16.00 | 9.0% | 1 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $15.95 | 9.0% | 1 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $15.66 | 8.8% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $177.95 | 10 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $58.66 | 3 | 2025 |
Source payment records
|
|||||
| ENTRESTO Normalized: entresto |
Drug | Novartis Pharmaceuticals Corporation | $38.25 | 2 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $38.07 | 2 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $19.38 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $17.50 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $17.50 | 1 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $16.11 | 1 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $16.11 | 1 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $16.11 | 1 | 2025 |
Source payment records
|
|||||
| IBSRELA Normalized: ibsrela |
Drug | Ardelyx, Inc. | $16.00 | 1 | 2025 |
Source payment records
|
|||||
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $15.95 | 1 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $15.66 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ENTRESTO entresto |
2025 | Entresto | 2024 | 12 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 233 | exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 19 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
18 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
106 | 20 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
28 | suppressed by CMS |
| Novartis Pharmaceuticals Corporation Exact reporting entity; no affiliate inference |
2025 | ENTRESTO open payments reported associated product |
CMS Open Payments — General Payments 9346 supporting records · 6254 recipient NPIs · example record 1200004797 |
Entresto · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
233 | 34 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
19 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
65 | 14 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
16 | 16 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 402 | 113 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 358 | 95 |
| Levothyroxine Sodium | Levothyroxine Sodium | 318 | 76 |
| Ezetimibe | Ezetimibe | 303 | 81 |
| Omeprazole | Omeprazole | 250 | 75 |
| Ozempic | Semaglutide | 233 | 34 |
| Losartan Potassium | Losartan Potassium | 203 | 47 |
| Pantoprazole Sodium | Pantoprazole Sodium | 181 | 47 |
| Amlodipine Besylate | Amlodipine Besylate | 177 | 51 |
| Alprazolam | Alprazolam | 160 | 34 |
| Fenofibrate | Fenofibrate | 148 | 38 |
| Metformin Hcl Er | Metformin Hcl | 146 | 37 |
| Duloxetine Hcl | Duloxetine Hcl | 130 | 33 |
| Prednisone | Prednisone | 115 | 83 |
| Tamsulosin Hcl | Tamsulosin Hcl | 115 | 36 |
| Metoprolol Succinate | Metoprolol Succinate | 112 | 31 |
| Montelukast Sodium | Montelukast Sodium | 112 | 25 |
| Lisinopril | Lisinopril | 109 | 40 |
| Jardiance | Empagliflozin | 106 | 20 |
| Meloxicam | Meloxicam | 106 | 29 |
| Simvastatin | Simvastatin | 101 | 27 |
| Hydrochlorothiazide | Hydrochlorothiazide | 98 | 29 |
| Pravastatin Sodium | Pravastatin Sodium | 97 | 21 |
| Escitalopram Oxalate | Escitalopram Oxalate | 93 | 23 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 93 | 18 |
| Fluoxetine Hcl | Fluoxetine Hcl | 91 | 23 |
| Trazodone Hcl | Trazodone Hcl | 89 | 29 |
| Metformin Hcl | Metformin Hcl | 88 | 25 |
| Gabapentin | Gabapentin | 83 | 24 |
| Fluticasone Propionate | Fluticasone Propionate | 80 | 44 |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 79 | 23 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 76 | 17 |
| Pregabalin | Pregabalin | 72 | 23 |
| Carvedilol | Carvedilol | 71 | 20 |
| Tizanidine Hcl | Tizanidine Hcl | 71 | 27 |
| Valsartan | Valsartan | 70 | 19 |
| Azithromycin | Azithromycin | 69 | 53 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 69 | 20 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 68 | 19 |
| Eliquis | Apixaban | 65 | 14 |
| Farxiga | Dapagliflozin Propanediol | 63 | 16 |
| Bupropion Xl | Bupropion Hcl | 62 | 16 |
| Furosemide | Furosemide | 62 | 23 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 60 | 26 |
| Citalopram Hbr | Citalopram Hydrobromide | 60 | 17 |
| Quetiapine Fumarate | Quetiapine Fumarate | 58 | suppressed |
| Famotidine | Famotidine | 57 | 15 |
| Ropinirole Hcl | Ropinirole Hcl | 54 | 13 |
| Tradjenta | Linagliptin | 53 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 53 | 19 |
| Clopidogrel | Clopidogrel Bisulfate | 51 | 17 |
| Potassium Chloride | Potassium Chloride | 50 | 15 |
| Estradiol | Estradiol | 48 | 13 |
| Januvia | Sitagliptin Phosphate | 48 | 12 |
| Tramadol Hcl | Tramadol Hcl | 46 | 16 |
| Sertraline Hcl | Sertraline Hcl | 44 | 14 |
| Allopurinol | Allopurinol | 43 | 14 |
| Finasteride | Finasteride | 42 | 15 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 41 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 41 | 15 |
| Clonazepam | Clonazepam | 40 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 40 | 11 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 38 | suppressed |
| Spironolactone | Spironolactone | 38 | 14 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 37 | suppressed |
| Vascepa | Icosapent Ethyl | 35 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 34 | 22 |
| Glipizide Er | Glipizide | 33 | suppressed |
| Temazepam | Temazepam | 32 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 31 | 25 |
| Xarelto | Rivaroxaban | 31 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 30 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 29 | suppressed |
| Celecoxib | Celecoxib | 29 | suppressed |
| Naproxen | Naproxen | 29 | suppressed |
| Sucralfate | Sucralfate | 29 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 28 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 28 | 26 |
| Trulicity | Dulaglutide | 28 | suppressed |
| Nexlizet | Bempedoic Acid/Ezetimibe | 26 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 26 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 26 | suppressed |
| Ondansetron Odt | Ondansetron | 25 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 25 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 24 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 24 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 24 | 20 |
| Azelastine Hcl | Azelastine Hcl | 23 | suppressed |
| Fluconazole | Fluconazole | 23 | 15 |
| Glimepiride | Glimepiride | 23 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 23 | suppressed |
| Repatha Sureclick | Evolocumab | 23 | suppressed |
| Amoxicillin | Amoxicillin | 22 | 14 |
| Oxybutynin Chloride | Oxybutynin Chloride | 22 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 20 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 20 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 20 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 19 | suppressed |
| Doxycycline Monohydrate | Doxycycline Monohydrate | 19 | 17 |
| Propranolol Hcl | Propranolol Hcl | 19 | suppressed |
| Rybelsus | Semaglutide | 19 | suppressed |
| Linzess | Linaclotide | 18 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 18 | 11 |
| Telmisartan | Telmisartan | 18 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 17 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 16 | suppressed |
| Chlorthalidone | Chlorthalidone | 16 | suppressed |
| Kerendia | Finerenone | 16 | suppressed |
| Lamotrigine | Lamotrigine | 16 | suppressed |
| Nifedipine Er | Nifedipine | 16 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 16 | 16 |
| Sildenafil Citrate | Sildenafil Citrate | 16 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 16 | suppressed |
| Estradiol (Twice Weekly) | Estradiol | 15 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 15 | suppressed |
| Metronidazole | Metronidazole | 15 | 12 |
| Aripiprazole | Aripiprazole | 14 | suppressed |
| Atenolol | Atenolol | 14 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 14 | suppressed |
| Glipizide | Glipizide | 14 | suppressed |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 14 | suppressed |
| Ibuprofen | Ibuprofen | 14 | suppressed |
| Oxcarbazepine | Oxcarbazepine | 14 | suppressed |
| Amlodipine-Atorvastatin | Amlodipine/Atorvastatin | 13 | suppressed |
| Clorazepate Dipotassium | Clorazepate Dipotassium | 13 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 13 | suppressed |
| Entresto | Sacubitril/Valsartan | 12 | suppressed |
| Lorazepam | Lorazepam | 12 | suppressed |
| Nexletol | Bempedoic Acid | 12 | suppressed |
| Nitroglycerin Patch | Nitroglycerin | 12 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 11 | suppressed |
| Glycopyrrolate | Glycopyrrolate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $177.95 · 10 records | Novartis Pharmaceuticals Corporation | ABRYSVO, COMIRNATY, ENTRESTO, IBSRELA, LEQVIO, MOUNJARO, Ozempic, PREVNAR 20, Rybelsus, VRAYLAR, Veozah, ZEPBOUND | 8 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Entresto play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error